Literature DB >> 28396545

Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.

Ahalieyah Anantharajah1, Julien M Buyck1, Charlotta Sundin2, Paul M Tulkens1, Marie-Paule Mingeot-Leclercq1, Françoise Van Bambeke3.   

Abstract

Type 3 secretion systems (T3SSs) are major virulence factors in Gram-negative bacteria. Pseudomonas aeruginosa expresses two T3SSs, namely, an injectisome (iT3SS) translocating effector proteins in the host cell cytosol and a flagellum (fT3SS) ensuring bacterial motility. Inhibiting these systems is an appealing therapeutic strategy for acute infections. This study examines the protective effects of the salicylidene acylhydrazide INP0341 and of the hydroxyquinoline INP1750 (previously described as T3SS inhibitors in other species) toward cytotoxic effects of P. aeruginosain vitro Both compounds reduced cell necrosis and inflammasome activation induced by reference strains or clinical isolates expressing T3SS toxins or only the translocation apparatus. INP0341 inhibited iT3SS transcriptional activation, including in strains with constitutive iT3SS expression, and reduced the total expression of toxins, suggesting it targets iT3SS gene transcription. INP1750 inhibited toxin secretion and flagellar motility and impaired the activity of the YscN ATPase from Yersinia pseudotuberculosis (homologous to the ATPase present in the basal body of P. aeruginosa iT3SS and fT3SS), suggesting that it rather targets a T3SS core constituent with high homology among iT3SS and fT3SS. This mode of action is similar to that previously described for INP1855, another hydroxyquinoline, against P. aeruginosa Thus, although acting by different mechanisms, INP0341 and INP1750 appear as useful inhibitors of the virulence of P. aeruginosa Hydroxyquinolines may have a broader spectrum of activity by the fact they act upon two virulence factors (iT3SS and fT3SS).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  NLRC4 inflammasome; Pseudomonas aeruginosa; flagella; inhibitors; type three secretion system; virulence

Mesh:

Substances:

Year:  2017        PMID: 28396545      PMCID: PMC5444141          DOI: 10.1128/AAC.02566-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  66 in total

Review 1.  Efflux pumps: their role in antibacterial drug discovery.

Authors:  O Lomovskaya; W J Watkins
Journal:  Curr Med Chem       Date:  2001-12       Impact factor: 4.530

2.  Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.

Authors:  Leslie Bailey; Asa Gylfe; Charlotta Sundin; Sandra Muschiol; Mikael Elofsson; Peter Nordström; Birgitta Henriques-Normark; Raimond Lugert; Anders Waldenström; Hans Wolf-Watz; Sven Bergström
Journal:  FEBS Lett       Date:  2007-01-17       Impact factor: 4.124

3.  Polarisation of type III translocation by Pseudomonas aeruginosa requires PcrG, PcrV and PopN.

Authors:  Charlotta Sundin; Johanna Thelaus; Jeanette E Bröms; Ake Forsberg
Journal:  Microb Pathog       Date:  2004-12-08       Impact factor: 3.738

Review 4.  Transcriptional regulation of the Pseudomonas aeruginosa type III secretion system.

Authors:  Timothy L Yahr; Matthew C Wolfgang
Journal:  Mol Microbiol       Date:  2006-09-21       Impact factor: 3.501

5.  Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments.

Authors:  E Frithz-Lindsten; Y Du; R Rosqvist; A Forsberg
Journal:  Mol Microbiol       Date:  1997-09       Impact factor: 3.501

6.  Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome.

Authors:  Edward A Miao; Dat P Mao; Natalya Yudkovsky; Richard Bonneau; Cynthia G Lorang; Sarah E Warren; Irina A Leaf; Alan Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-01       Impact factor: 11.205

7.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

Review 8.  Recognition of bacteria by inflammasomes.

Authors:  Jakob von Moltke; Janelle S Ayres; Eric M Kofoed; Joseph Chavarría-Smith; Russell E Vance
Journal:  Annu Rev Immunol       Date:  2012-11-26       Impact factor: 28.527

9.  Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium.

Authors:  Aurel Negrea; Eva Bjur; Sofia Eriksson Ygberg; Mikael Elofsson; Hans Wolf-Watz; Mikael Rhen
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

10.  Small molecule inhibitors of the Yersinia type III secretion system impair the development of Chlamydia after entry into host cells.

Authors:  Sandra Muschiol; Staffan Normark; Birgitta Henriques-Normark; Agathe Subtil
Journal:  BMC Microbiol       Date:  2009-04-21       Impact factor: 3.605

View more
  14 in total

Review 1.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

2.  Novel Noncompetitive Type Three Secretion System ATPase Inhibitors Shut Down Shigella Effector Secretion.

Authors:  Heather B Case; Dominic S Mattock; Bill R Miller; Nicholas E Dickenson
Journal:  Biochemistry       Date:  2020-06-30       Impact factor: 3.162

3.  The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo.

Authors:  Pia Uusitalo; Ulrik Hägglund; Elin Rhöös; Henrik Scherman Norberg; Mikael Elofsson; Charlotta Sundin
Journal:  J Antibiot (Tokyo)       Date:  2017-06-07       Impact factor: 2.649

Review 4.  Promises and Challenges of the Type Three Secretion System Injectisome as an Antivirulence Target.

Authors:  Alyssa C Fasciano; Lamyaa Shaban; Joan Mecsas
Journal:  EcoSal Plus       Date:  2019-02

5.  Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.

Authors:  Hanh N Lam; Tannia Lau; Adam Lentz; Jessica Sherry; Alejandro Cabrera-Cortez; Karen Hug; Annalyse Lalljie; Joanne Engel; R Scott Lokey; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.938

6.  Antimicrobial resistance and virulence of Pseudomonas spp. among healthy animals: concern about exolysin ExlA detection.

Authors:  Lidia Ruiz-Roldán; Beatriz Rojo-Bezares; María de Toro; María López; Paula Toledano; Carmen Lozano; Gabriela Chichón; Lydia Alvarez-Erviti; Carmen Torres; Yolanda Sáenz
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

7.  An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia.

Authors:  Jessica M Morgan; Hanh N Lam; Jocelyn Delgado; Justin Luu; Sina Mohammadi; Ralph R Isberg; Helen Wang; Victoria Auerbuch
Journal:  Front Cell Infect Microbiol       Date:  2018-11-22       Impact factor: 5.293

8.  Great phenotypic and genetic variation among successive chronic Pseudomonas aeruginosa from a cystic fibrosis patient.

Authors:  Carmen Lozano; José Manuel Azcona-Gutiérrez; Françoise Van Bambeke; Yolanda Sáenz
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

9.  Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium.

Authors:  Qianghua Lv; Xiao Chu; Xinyu Yao; Kelong Ma; Yong Zhang; Xuming Deng
Journal:  J Cell Mol Med       Date:  2019-05-08       Impact factor: 5.310

10.  Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice.

Authors:  Anna B Sheremet; Naylia A Zigangirova; Egor S Zayakin; Sergei I Luyksaar; Lydia N Kapotina; Ludmila N Nesterenko; Natalie V Kobets; Alexander L Gintsburg
Journal:  Biomed Res Int       Date:  2018-09-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.